Literature DB >> 17580004

Anticonvulsant hypersensitivity syndrome: identification and management.

Tricia Y Ting1.   

Abstract

Anticonvulsant hypersensitivity syndrome is a rare and potentially life-threatening delayed-type immune reaction with few proven treatments beyond early recognition and immediate discontinuation of the causative drug. Intravenous immunoglobulin has been shown in some uncontrolled studies to hasten recovery and may prove safer than systemic corticosteroid therapy, which carries a significant risk for increased mortality from sepsis. Identification and counseling of at-risk patients through knowledge of potential drug cross-sensitivity and familial susceptibility may help prevent this dangerous idiosyncratic drug reaction.

Entities:  

Year:  2007        PMID: 17580004     DOI: 10.1007/s11940-007-0010-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  14 in total

1.  Successful re-introduction of lamotrigine after initial rash.

Authors:  F M Besag; G Y Ng; F Pool
Journal:  Seizure       Date:  2000-06       Impact factor: 3.184

2.  Cross sensitivity of skin rashes with antiepileptic drugs.

Authors:  C Hyson; M Sadler
Journal:  Can J Neurol Sci       Date:  1997-08       Impact factor: 2.104

3.  Adverse reactions to carbamazepine managed by desensitisation.

Authors:  H Smith; R Newton
Journal:  Lancet       Date:  1985-03-30       Impact factor: 79.321

4.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.

Authors:  N H Shear; S P Spielberg
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  Current understanding of delayed anticonvulsant hypersensitivity reactions.

Authors:  Gregory Krauss
Journal:  Epilepsy Curr       Date:  2006 Mar-Apr       Impact factor: 7.500

6.  Spectrum of anticonvulsant hypersensitivity syndrome: controversy of treatment.

Authors:  Wing-Cheong Lee; Joy Lok-Sum Leung; Cheuk-Wing Fung; Brian Hon-Yin Chung; Virginia Wong
Journal:  J Child Neurol       Date:  2004-08       Impact factor: 1.987

7.  Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression.

Authors:  Nicolas Bachot; Jean Revuz; Jean-Claude Roujeau
Journal:  Arch Dermatol       Date:  2003-01

Review 8.  Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature.

Authors:  Denise W Metry; Peter Jung; Moise L Levy
Journal:  Pediatrics       Date:  2003-12       Impact factor: 7.124

9.  Predictors of Lamotrigine-associated rash.

Authors:  Lawrence J Hirsch; David B Weintraub; Richard Buchsbaum; Hilary T Spencer; Tara Straka; Melissa Hager; Stanley R Resor
Journal:  Epilepsia       Date:  2006-02       Impact factor: 5.864

10.  Rechallenge with lamotrigine after initial rash.

Authors:  S J Tavernor; I C Wong; R Newton; S W Brown
Journal:  Seizure       Date:  1995-03       Impact factor: 3.184

View more
  2 in total

Review 1.  In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 2.  Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) induced by carbamazepine: a case report and literature review.

Authors:  Nissrine E L omairi; Sanae Abourazzak; Sanae Chaouki; Samir Atmani; Moustapha Hida
Journal:  Pan Afr Med J       Date:  2014-05-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.